[{"id":"333c53ae-6310-43e6-88cd-edfda84ac25b","acronym":"","url":"https://clinicaltrials.gov/study/NCT01101581","created_at":"2021-01-18T04:21:31.821Z","updated_at":"2024-07-02T16:36:26.198Z","phase":"Phase 1/2","brief_title":"Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL","source_id_and_acronym":"NCT01101581","lead_sponsor":"Gilead Sciences","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LymphoCide Y-90 (epratuzumab Y-90) • Veltucyn (veltuzumab)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 05/01/2010","start_date":" 05/01/2010","primary_txt":" Primary completion: 12/01/2016","primary_completion_date":" 12/01/2016","study_txt":" Completion: 03/01/2017","study_completion_date":" 03/01/2017","last_update_posted":"2021-08-18"},{"id":"9a01ff71-e3b5-4c99-8c92-dbec1cce9a9a","acronym":"","url":"https://clinicaltrials.gov/study/NCT00596804","created_at":"2021-01-18T02:12:34.996Z","updated_at":"2024-07-02T16:36:26.146Z","phase":"Phase 1/2","brief_title":"Safety Study of Different Doses of hA20 (Veltuzumab) in CD20+ Non-Hodgkin's Lymphoma","source_id_and_acronym":"NCT00596804","lead_sponsor":"Gilead Sciences","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Veltucyn (veltuzumab)"],"overall_status":"Completed","enrollment":" Enrollment 39","initiation":"Initiation: 03/01/2004","start_date":" 03/01/2004","primary_txt":" Primary completion: 11/01/2007","primary_completion_date":" 11/01/2007","study_txt":" Completion: 11/01/2007","study_completion_date":" 11/01/2007","last_update_posted":"2021-08-18"},{"id":"75e93e38-4d1e-4138-831c-719c6af4edad","acronym":"","url":"https://clinicaltrials.gov/study/NCT00285428","created_at":"2021-01-18T00:58:21.584Z","updated_at":"2024-07-02T16:36:26.227Z","phase":"Phase 1/2","brief_title":"Study of hA20 (Humanized Anti-CD20) in Patients With CD20+ Non-Hodgkin's Lymphoma","source_id_and_acronym":"NCT00285428","lead_sponsor":"Gilead Sciences","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Veltucyn (veltuzumab)"],"overall_status":"Completed","enrollment":" Enrollment 82","initiation":"Initiation: 09/01/2004","start_date":" 09/01/2004","primary_txt":" Primary completion: 10/01/2007","primary_completion_date":" 10/01/2007","study_txt":" Completion: 10/01/2007","study_completion_date":" 10/01/2007","last_update_posted":"2021-08-17"},{"id":"8ff074b0-3b16-48a8-96f5-5fc1ed9fb6cf","acronym":"","url":"https://clinicaltrials.gov/study/NCT00546793","created_at":"2021-01-18T01:59:26.165Z","updated_at":"2024-07-02T16:36:26.283Z","phase":"Phase 1/2","brief_title":"Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL","source_id_and_acronym":"NCT00546793","lead_sponsor":"Gilead Sciences","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Veltucyn (veltuzumab)"],"overall_status":"Completed","enrollment":" Enrollment 32","initiation":"Initiation: 01/01/2008","start_date":" 01/01/2008","primary_txt":" Primary completion: 03/01/2013","primary_completion_date":" 03/01/2013","study_txt":" Completion: 03/01/2013","study_completion_date":" 03/01/2013","last_update_posted":"2021-08-16"}]